Kaleido Biosciences to Present at the 38th Annual J.P. Morgan Healthcare Conference

LEXINGTON, Mass., Jan. 06, 2020 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a chemistry-driven approach to leveraging the microbiome organ to treat disease and improve human health, today announced that Alison Lawton, President and Chief Executive Officer, will present at the 38th Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2020 at 4:00 p.m. PT (7:00 p.m.

Metadata
Provider: 
GlobeNewswire, Inc.GlobeNewswire, Inc.
Retrieved on: 
Monday, January 6, 2020
Information
Tags: 
Branches of biology, Medicine, Microbiomes, Bacteriology, Microbiology, Organisms, Bacteria, Microbiota, Disease
Geotags: 
Lexington, Ma, Us
Organisation: 
KALEIDO BIOSCIENCES
Summary
Key Points: 
  • LEXINGTON, Mass., Jan. 06, 2020 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a chemistry-driven approach to leveraging the microbiome organ to treat disease and improve human health, today announced that Alison Lawton, President and Chief Executive Officer, will present at the 38th Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2020 at 4:00 p.m. PT (7:00 p.m.
  • A live audio webcast of the presentation and question and answer sessioncan be accessed on the Investors & Media section of Kaleidos website at https://investors.kaleido.com/events-presentations .
  • Kaleido Biosciencesis a clinical-stage healthcare company with a differentiated, chemistry-driven approach to leveraging the microbiome organ to treat disease and improve human health.
  • Kaleido is advancing a broad pipeline of MMT candidates with the potential to address a variety of diseases and conditions with significant unmet patient needs.



LEXINGTON, Mass., Jan. 06, 2020 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a chemistry-driven approach to leveraging the microbiome organ to treat disease and improve human health, today announced that Alison Lawton, President and Chief Executive Officer, will present at the 38th Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2020 at 4:00 p.m. PT (7:00 p.m. ET) in San Francisco, CA.

A live audio webcast of the presentation and question and answer session can be accessed on the Investors & Media section of Kaleido’s website at https://investors.kaleido.com/events-presentations. An archived replay will be available for 30 days following the event.

About Kaleido Biosciences

Kaleido Biosciences is a clinical-stage healthcare company with a differentiated, chemistry-driven approach to leveraging the microbiome organ to treat disease and improve human health. The Company has built a human-centric proprietary product platform to enable the rapid and cost-efficient discovery and development of novel Microbiome Metabolic Therapies (MMT™). MMTs are designed to modulate the metabolic output and profile of the microbiome by driving the function and distribution of the organ’s existing microbes. Kaleido is advancing a broad pipeline of MMT candidates with the potential to address a variety of diseases and conditions with significant unmet patient needs. To learn more, visit https://kaleido.com/.

Contact

Amy Reilly
617-890-5721
[email protected]

Primary Logo
Copyright: 
2020 GlobeNewswire, Inc.. All Rights Reserved.